Welcome to the CMC Strategy Forum

Transcription

Welcome to the CMC Strategy Forum
Welcome to the CMC Strategy Forum
We are pleased to welcome you to the CMC Strategy Forum. The purpose of the CMC Strategy Forum
is to provide a venue for biotechnology/biological product discussion. The meetings focus on relevant
CMC issues throughout the lifecycle of a product and thereby foster collaborative technical and
regulatory interactions. The Forum strives to share information with the regulatory agencies to assist
them in merging good scientific and regulatory practices. Outcomes of the Forum meetings are
published in an appropriate peer-reviewed journal.
Each meeting will focus on a CMC related issue such as product characterization, comparability,
specifications, etc. The format of each meeting will consist of case studies and presentations by Industry
and/or FDA experts to introduce the topic and the key issues of concern. Breakout sessions will then be
conducted to allow for additional discussion on the technical and regulatory details of the topics. It is
envisioned that the final outcome of the workshop discussions will be the development of a document to
be submitted to the appropriate Regulatory Agency designees for their consideration in developing
and/or clarifying good regulatory practice guidelines for biotechnology derived products.
The success of the CMC Strategy Forum will depend on your active participation in discussing and
raising issues pertaining to development of biologics. We encourage you to participate wholeheartedly
in the workshops that have been designed to stimulate exchange of ideas and information.
We would like to thank the speakers who are giving generously of their time and resources, and to you,
for your attendance. We acknowledge the generosity of our program partners: AbbVie, Inc., Amgen
Inc., Biogen Idec, Eli Lilly and Company, Genentech, a Member of the Roche Group, Genzyme, A
Sanofi Company, Janssen Pharmaceutical R&D, LLC, MedImmune, National Institute of Standards and
Technology (NIST) and Pfizer Inc. We are grateful for the expert management from CASSS and the
audio-visual expertise of Michael Johnstone from MJ Audio-Visual Productions. Their experience and
guidance in the preparation of this Forum have been invaluable.
ACKNOWLEDGEMENTS
CMC STRATEGY FORUM GLOBAL STEERING COMMITTEE
Siddharth Advant, Kemwell Biopharma, USA
John Dougherty, Eli Lilly and Company, USA
Steven Kozlowski, CDER, FDA, USA
Junichi Koga, Daiichi Sankyo Co., Ltd., Japan
Rohin Mhatre, Biogen Idec, USA
Anthony Mire-Sluis, Amgen Inc., USA
Wassim Nashabeh, F. Hoffmann-La Roche Ltd., Switzerland
Ilona Reischl, BASG/AGES, Austria
Anthony Ridgway, Health Canada, Canada
Nadine Ritter, Global Biotech Experts, LLC, USA
Thomas Schreitmüller, F. Hoffmann-La Roche Ltd., Switzerland
Mark Schenerman, MedImmune, USA
Karin Sewerin, BioTech Development AB, Sweden
CMC STRATEGY FORUM NORTH AMERICA PROGRAM COMMITTEE
Siddharth Advant, Kemwell Biopharma
Yves Aubin, Health Canada
John Bishop, CBER, FDA
Barry Cherney, Amgen Inc.
JR Dobbins, Eli Lilly and Company
Julia Edwards, Alnylam Pharmaceuticals, Inc.
John Hennessey, Novadigm Therapeutics, Inc.
Joseph Kutza, MedImmune
Kimberly May, Merck & Co., Inc.
Anthony Mire-Sluis, Amgen Inc.
Stefanie Pluschkell, Pfizer, Inc.
Nadine Ritter, Global Biotech Experts, LLC
Reb Russell, Bristol-Myers Squibb Company
Dieter Schmalzing, Genentech, a Member of the Roche Group
Timothy Schofield, MedImmune
Zahra Shahrokh, ZDev Consulting
Jeffrey Staecker, Genzyme Corporation, a Sanofi company
Patrick Swann, CDER, FDA
Andrew Weiskopf, Biogen Idec
The Organizing Committee gratefully acknowledges the
pharmaceutical and biotechnology industry for their generous support
of the CMC Strategy Forum series:
SUSTAINING DIAMOND PROGRAM PARTNER
Genentech, a Member of the
Roche Group
SUSTAINING PLATINUM PROGRAM PARTNER
Biogen Idec
SUSTAINING GOLD PROGRAM PARTNER
Abb Vie, Inc.
SUSTAINING SILVER PROGRAM PARTNER
Pfizer, Inc.
PROGRAM PARTNERS
Amgen Inc.
Eli Lilly and Company
Genzyme, A Sanofi Company
Janssen Pharmaceutical R & D, LLC
MedImmune
National Institute of Standards and
Technology (NIST)
LEADING MEDIA PARTNERS
BioProcess International
International Pharmaceutical Quality
MEDIA PARTNERS
American Laboratory
American Pharmaceutical Review
The Analytical Scientist
BioProcessing Journal
BioTech International
Genetic Engineering & Biotechnology News
LCGC North America
The Medicine Maker
The Pathologist
Pharmaceutical Outsourcing
RSC Advances
separationsNOW.com
Technology Networks Limited
Forum Abstract
Current Perspectives on Host Cell Protein Analysis and Control: Science, Risks and Regulations
FORUM CO-CHAIRS:
Dieter Schmalzing, Genentech, a Member of the Roche Group, USA
Zahra Shahrokh, STC Biologics, USA
SCIENTIFIC ORGANIZING COMMITTEE:
John Bishop, CBER, FDA, USA
Bruce Meiklejohn, Eli Lilly and Company, USA
Rashmi Rawat, CDER, FDA, USA
Nadine Ritter, Global Biotech Experts, LLC, USA
Victoria Sluzky, BioMarin Pharmaceutical Inc., USA
For thorough understanding, effective removal and suitable control of host cell proteins (HCPs) in
recombinant biotechnology products, state-of-the art analytics are key to properly guide process
development and to minimize potential risks to patients such as immunogenic response.
Arrays of classic and state-of-the art analytical techniques and approaches are being used to establish
control strategies for host cell proteins. They include 2D gel electrophoresis (direct stains or labeled comixtures), 2D-HPLC, immunoassays (commercial kits, in-house platform and product-specific methods)
and increasingly, mass spectrometry. Nonetheless, the inherent complexity of hundreds of HCPs
challenges the capability of each method to detect, identify and quantify HCPs, some of which can be
highly similar and others significantly different in molecular characteristics, abundance and affinity to
antibodies raised against them for immunoassays. The latter, for example, limits the capability of
immunoassay methods to accurately represent the HCP population and content, resulting in some HCPs
potentially evading detection. Moreover, some HCPs may co-purify with the product even with affinity
binding steps, if their molecular properties are sufficiently similar.
This one-day Forum integrates perspectives on the science, product quality/safety and regulatory aspects
of HCPs and their control. Specifically, it aims to provide a critical evaluation of the existing and
emerging technologies for characterization, clearance, comparability and control of host cell proteins in
biotechnology derived products. Case studies will be presented that exemplify best practices to
maximize HCP coverage, the utility of product-specific versus platform methods and the applications of
mass spectrometry to aid in detection and estimation of HCPs that evade immunoassays. In addition,
industry and regulatory agency experiences on risks to product quality and manufacturing consistency
with potential impact on clinical outcomes will be shared. Current regulatory expectations and
pharmacopeia efforts will be presented and discussed.
CMC Strategy Forum Program Summary
Current Perspectives on Host Cell Protein Analysis and Control: Science, Risks and Regulations
Monday, January 26, 2015
07:30 – 17:00
Registration on the Mezzanine Level
07:30 – 08:30
Breakfast in the
08:30 – 08:45
CASSS Welcome and Introductory Comments in the
Nadine Ritter, Global Biotech Experts, LLC
CMC Strategy Forum Welcome and Introductory Comments in the
Zahra Shahrokh, STC Biologics
Best Practices and Emerging Analytical Technologies to Achieve Optimal Detection of HCPs in
Process and Product
Workshop Session One in the
Session Chairs: ????
08:45 – 09:15
Advances in HCP Analytics (review of current and newer methodologies to
assess and improve coverage)
Florian Wolschin, Sandoz GmbH, Kundl, Austria (invited)
09:15 – 09:45
Case Examples of Immunogenic HCPs (application of mass spectrometry to
characterization of HCPs and facilitating process improvement)
Kevin Van Cott, University of Nebraska, Lincoln, NE USA (invited)
09:45 – 10:15
Product-specific versus Platform Assays: Pros, Cons and Challenges
Martin Vanderlaan, Genentech, a Member of the Roche Group, South San
Francisco, CA USA
10:15 – 10:45
AM Break in the
10:45 – 12:15
PANEL DISCUSSION – Questions and Answers
Kevin Van Cott, University of Nebraska, Lincoln, NE USA (invited)
Martin Vanderlaan, Genentech, a Member of the Roche Group, South San
Francisco, CA USA
Florian Wolschin, Sandoz GmbH, Kundl, Austria (invited)
TBD industry or regulator
TBD regulator
TBD regulator
12:15 – 13:45
Hosted Lunch in the
Monday, January 26 continued…
Clinical Experience and Regulatory Expectations for HCP Testing and Control
Workshop Session Two in the
Session Chairs: ?????
13:45 – 14:15
USA Regulatory Experiences and Expectations – Blood Products and
Monoclonal Antibodies
Laurie Graham, CBER, FDA, Silver Spring, MD USA
Alexey Khrenov, CBER, FDA, Silver Spring, MD USA
14:15 – 14:45
European Regulatory Experiences and Expectations – Blood Products and
Monoclonal Antibodies
Jörg Engelbergs Paul-Ehrlich-Institut, Langen, Germany
Erika Friedl, Paul-Ehrlich-Institut, Langen, Germany (invited)
14:45 – 15:15
USP and EDQM Host Cell Protein Guidance Documents – Convergence and
Differences
Kowid Ho, F. Hoffmann-La Roche Ltd., Basel, Switzerland
Anthony Mire-Sluis, Amgen Inc., Thousand Oaks, CA USA
15:15 – 15:45
PM Break in the
15:45 – 17:15
PANEL DISCUSSION – Questions and Answers
Oliver Anderka, Novartis Pharma AG, Switzerland (invited)
Jörg Engelbergs Paul-Ehrlich-Institut, Germany
Erika Friedl, Paul-Ehrlich-Institut, Germany
Laurie Graham, CBER, FDA, USA
Nancy Green, Health Canada, Canada (invited)
Kowid Ho, F. Hoffmann-La Roche Ltd., Switzerland
Alexey Khrenov, CBER, FDA, USA
Anthony Mire-Sluis, Amgen Inc., USA
17:15 – 17:45
Recap of Program
Summary Slide Presentation
TBD
17:45 – 18:00
Invitation to CMC Strategy Forum July 2015
18:00 – 19:00
Networking Reception in the Chinese Room
Presenters Abstracts